Abstract
This study has been carried out to evaluate the efficacy of Adoptive Immunotherapy (AI) with TIL (Tumor Infiltrating Lymphocytes) cells and recombinant Interleukin-2 (rIL-2) in patients who underwent surgery for non small cell lung cancer (NSCLC) at Stage II, IIIa or IIIb. Seventy-one patients were stratified according to the disease Stage, randomized and treated with AI or standard therapies (Chemo-radiotherapy in Stage III; no therapy in Stage II). TIL cells, obtained from the removed specimens, were in vitro expanded and infused i.v. Subcutaneous administration of rIL-2, starting at the TIL infusion day, lasted for 3 months. For Stage II patients, the survival curve in the AI Group was similar to that in the Control Group. For Stage IIIa patients, survival tended to be higher in the AI Group with respect to the Control Group. For Stage IIIb patients, survival was significantly (p <0.05) better in the AI Group. The Performance Status, as far as Stage III patients are concerned, was improved in the AI Group, with respect to the Control Group. The number of intrathoracic recurrences was lower (50%) in patients undergoing AI, while no difference between Groups was found for distant relapse.
| Original language | Italian |
|---|---|
| Pages (from-to) | 82-87 |
| Number of pages | 6 |
| Journal | Chirurgia |
| Volume | 8 |
| Issue number | 1-2 |
| Publication status | Published - 1995 |
Fingerprint
ASJC Scopus subject areas
- Surgery
Cite this
L'IMMUNOTERAPIA ADOTTIVA NEL TRATTAMENTO POST-CHIRURGICO DEL CARCINOMA POLMONARE NON A PICCOLE CELLULE. / Ratto, G. B.; Melioli, C.; Fantino, G.; Tassara, E.; Ponte, M.; Angelini, M.; Spessa, E.; Semino, C.; Rovida, S.
In: Chirurgia, Vol. 8, No. 1-2, 1995, p. 82-87.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - L'IMMUNOTERAPIA ADOTTIVA NEL TRATTAMENTO POST-CHIRURGICO DEL CARCINOMA POLMONARE NON A PICCOLE CELLULE
AU - Ratto, G. B.
AU - Melioli, C.
AU - Fantino, G.
AU - Tassara, E.
AU - Ponte, M.
AU - Angelini, M.
AU - Spessa, E.
AU - Semino, C.
AU - Rovida, S.
PY - 1995
Y1 - 1995
N2 - This study has been carried out to evaluate the efficacy of Adoptive Immunotherapy (AI) with TIL (Tumor Infiltrating Lymphocytes) cells and recombinant Interleukin-2 (rIL-2) in patients who underwent surgery for non small cell lung cancer (NSCLC) at Stage II, IIIa or IIIb. Seventy-one patients were stratified according to the disease Stage, randomized and treated with AI or standard therapies (Chemo-radiotherapy in Stage III; no therapy in Stage II). TIL cells, obtained from the removed specimens, were in vitro expanded and infused i.v. Subcutaneous administration of rIL-2, starting at the TIL infusion day, lasted for 3 months. For Stage II patients, the survival curve in the AI Group was similar to that in the Control Group. For Stage IIIa patients, survival tended to be higher in the AI Group with respect to the Control Group. For Stage IIIb patients, survival was significantly (p <0.05) better in the AI Group. The Performance Status, as far as Stage III patients are concerned, was improved in the AI Group, with respect to the Control Group. The number of intrathoracic recurrences was lower (50%) in patients undergoing AI, while no difference between Groups was found for distant relapse.
AB - This study has been carried out to evaluate the efficacy of Adoptive Immunotherapy (AI) with TIL (Tumor Infiltrating Lymphocytes) cells and recombinant Interleukin-2 (rIL-2) in patients who underwent surgery for non small cell lung cancer (NSCLC) at Stage II, IIIa or IIIb. Seventy-one patients were stratified according to the disease Stage, randomized and treated with AI or standard therapies (Chemo-radiotherapy in Stage III; no therapy in Stage II). TIL cells, obtained from the removed specimens, were in vitro expanded and infused i.v. Subcutaneous administration of rIL-2, starting at the TIL infusion day, lasted for 3 months. For Stage II patients, the survival curve in the AI Group was similar to that in the Control Group. For Stage IIIa patients, survival tended to be higher in the AI Group with respect to the Control Group. For Stage IIIb patients, survival was significantly (p <0.05) better in the AI Group. The Performance Status, as far as Stage III patients are concerned, was improved in the AI Group, with respect to the Control Group. The number of intrathoracic recurrences was lower (50%) in patients undergoing AI, while no difference between Groups was found for distant relapse.
KW - Immunotherapy
KW - Interleukin-2
KW - Lung neoplasms
KW - Lymphocytes
UR - http://www.scopus.com/inward/record.url?scp=0029008634&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029008634&partnerID=8YFLogxK
M3 - Articolo
VL - 8
SP - 82
EP - 87
JO - Chirurgia (Turin)
JF - Chirurgia (Turin)
SN - 0394-9508
IS - 1-2
ER -